Tag:

Pharma CEO pay

Latest Headlines

Latest Headlines

Big Pharma execs top highest-paid Swiss list

Who tops the list of highest-paid Swiss executives? None other than pharma's own Daniel Vasella (photo), CEO of Novartis. Vasella's 2008 compensation grew by more than 20 percent from 2007, to 20.5

Merck chief's pension mushrooms by $10M

Merck CEO Dick Clark saw his pension benefit rise by nearly $10 million to $21.7 million in 2008, the Wall Street Journal reports in a survey of companies whose stock prices fell but executive

Disgraced ex-Astra CEO must forfeit pay

The financial industry may not be clawing back salary and bonuses from the bankers whose wild behavior cost their companies money. But you can't say the same about Big Pharma. Lars Bildman (

Schering execs in line for $107M-plus

Just how much do Schering-Plough execs stand to gain from the $41 billion Merck merger? The final numbers are in--and very official, having been reported to the Securities & Exchange Commission

Glaxo investors bless exec-pay plans

We're all familiar with the brouhaha that occasionally attended Jean-Pierre Garnier's annual pay package. The ex-chief of GlaxoSmithKline drew shareholder ire for bonuses and stock awards they

Will GSK investors revolt over Garnier bonus?

A U.K. shareholder group is up in arms over Jean-Pierre Garnier's (photo) bonus. Sound like a broken record? Or like a news story from a time capsule circa, oh, 2003? Nope, it's today's story--and

Top 15 Big Pharma Paychecks of 2008

Every year, executive salaries cause a flap as industry watchers compare who makes what, who got a raise and who's spending the most on air travel, security, drivers and the like. Inevitably, the

Clawbacks chomp into Fred Hassan's pay

Clawbacks can be hell. Just ask Schering-Plough chief Fred Hassan (photo), who took a big hit to his 2008 compensation because, to speak technically, his stock tanked. Under Schering's pay policy,

King execs reap 12% more pay in 2008

Proxy season continues. Today's entry: King Pharmaceuticals, whose executives' pay leapt 12.3 percent, despite a big drop in revenues and a net loss of $333 million on acquisition charges. At least

Pfizer shareholders want "say on pay"

Pfizer shareholders are on the cutting edge. At yesterday's annual meeting, they approved a proposal to ask the board of directors for an advisory vote on executive compensation. (They also asked for